Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 16/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | FGR | P09769 | 1/20 | 0.68 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | TEC | P42680 | 1/20 | 0.68 |
| ▸ | TXK | P42681 | 1/20 | 0.68 |
| ▸ | BLK | P51451 | 1/20 | 0.68 |
| ▸ | BMX | P51813 | 1/20 | 0.68 |
| ▸ | ITK | Q08881 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333926 | 0.90 | BTK (1.00) | BTKJAK2YES1CYP3A4FGR | |
| SCHEMBL16333658 | 0.90 | BTK (1.00) | BTKJAK2YES1CYP3A4FGR | |
| SCHEMBL16320256 | 0.89 | BTK (1.00) | BTKJAK2YES1CYP3A4FGR | |
| SCHEMBL16333936 | 0.86 | BTK (1.00) | BTKJAK2YES1CYP3A4FGR | |
| SCHEMBL16334388 | 0.85 | BTK (0.82) | BTKJAK2YES1CYP3A4FGR | |
| SCHEMBL16333976 | 0.84 | BTK (1.00) | BTKJAK2YES1CYP3A4FGR | |
| SCHEMBL16334571 | 0.83 | BTK (0.77) | BTKJAK2TECTXKBLK | |
| SCHEMBL16339297 | 0.82 | BTK (1.00) | BTKJAK2TECTXKBLK | |
| SCHEMBL16320070 | 0.81 | BTK (1.00) | BTKJAK2YES1CYP3A4FGR | |
| SCHEMBL16319977 | 0.81 | BTK (1.00) | BTKJAK2YES1CYP3A4FGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714234-B2 | Carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-25 | — | — | US | claimed |
| EP-3013815-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | claimed |
| US-20160200710-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | claimed |
| EP-3013815-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-04 | — | — | EP | claimed |
| WO-2014210087-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | claimed |
| US-9714234-B2 | Carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714234-B2 | Carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-25 | — | — | US | disclosed |
| EP-3013815-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-3013815-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160200710-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200710-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3013815-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014210087-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210087-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200710-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, SYK | BTK 1/4885JAK2 6/4885YES1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.